Abstract 1871
Background
Much of the work of a busy oncology day unit is undocumented, especially the work involved in phone triage during the working hours of 8am to 6pm. Phone calls from patients, their family doctors, palliative care teams, or from within the Hospital itself seeking advice form the majority of this aspect of the Specialist Oncology Nurse and Staff Nurses’ time. This project was performed to assess the nature of these calls and the broad advice given to the callers so that a dedicated Acute Review Specialist Oncology Nurse Clinic could be developed.
Methods
In conjunction with key oncology nurses and their medical oncologist colleagues a log to capture each answered call was developed. This centred on the date and time of the call, the source, the issue raised, the advice given, if advised to go to the Emergency Room the reason why, and other actions that were necessary. A form was completed per answered call, and collected at the end of the day. Data was recorded on a spreadsheet. All forms were annonymised with regard to patient identifiers. The forms were focused on whether the issue was successfully addressed within the day unit, the Hospital’s emergency room, the community services, or whether solely by the advice given over the telephone.
Results
A sample size of 252 incoming answered calls by the Oncology Nursing Staff to the Nurses’ station was analysed. Just over half these calls (52%) were made by patients/family members. Other calls related to internal questions such as from Interventional Radiology or other diagnostic areas of the Hospital (26%), pharmacies (7%), and family doctors (4%). The other 11% of calls were mainly from wards relating to advice on inpatients or seeking consults. Of the unwell patients calling for advice, near half (48%) were seeking advice on what action to take: stay at home or come to Hospital. 35% of patients were seeking either a new appointment or change in appointment date. The remaining 17% of patients were seeking non-emergency review by the medical oncology team.
Conclusions
This analysis of answered calls highlights the need for involvement of experienced oncology nurses in the triage of phone calls to a busy oncology day unit, and the need to develop an Acute Review Clinic, managed by an experienced oncology nurse specialist.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Beaumont Hospital Cancer Centre.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1285 - Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumors.
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
3808 - GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis
Presenter: Pierpaolo Correale
Session: Poster Display session 3
Resources:
Abstract
5677 - Immune correlates in peripheral blood samples in a preoperative window of opportunity randomized trial of nivolumab with or without tadalafil in resectable squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Larry Harshyne
Session: Poster Display session 3
Resources:
Abstract
4854 - Phase 1 evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies
Presenter: John Powderly
Session: Poster Display session 3
Resources:
Abstract
4344 - Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-squamous NSCLC
Presenter: Arun Rajan
Session: Poster Display session 3
Resources:
Abstract
4555 - Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumors: preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts
Presenter: Henry Conter
Session: Poster Display session 3
Resources:
Abstract
3012 - Excellent CBR and Prolonged PFS in Non-Squamous NSCLC with Oral CA-170, an Inhibitor of VISTA and PD-L1
Presenter: Vivek Radhakrishnan
Session: Poster Display session 3
Resources:
Abstract
2536 - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
Presenter: Christophe Le Tourneau
Session: Poster Display session 3
Resources:
Abstract
1845 - Induction of tumor-infiltrating functional CD8 positive cells and PD-L1 expression in esophageal cancer by S-588410
Presenter: Takashi Kojima
Session: Poster Display session 3
Resources:
Abstract
5043 - Comprehensive results of a Phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer
Presenter: Ursula Wiedermann
Session: Poster Display session 3
Resources:
Abstract